Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Fenofibrate for Treating Diabetic Eye Disease

Rafael Simó, Cristina Hernández

Diabetes 2023;72(7):838–840

https://doi.org/10.2337/dbi22-0037

Published: 20 June 2023

View article titled, Fenofibrate for Treating Diabetic Eye Disease

Journal Articles

In This Issue of Diabetes

Max Bingham, PhD

Diabetes 2023;72(7):823–824

https://doi.org/10.2337/db23-ti07

Published: 20 June 2023

View article titled, In This Issue of Diabetes

Journal Articles

Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Lijie Dong, Rui Cheng, Xiang Ma, Wentao Liang, Yaru Hong, Hui Li, Kelu Zhou, Yanhong Du, Yusuke Takahashi, Xiaomin Zhang, Xiao-rong Li, Jian-xing Ma

Diabetes 2023;72(7):958–972

https://doi.org/10.2337/db22-0654

Published: 14 April 2023

View article titled, Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Journal Articles

Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

Calesta Hui Yi Teo, Molly Tzu-Yu Lin, Isabelle Xin Yu Lee, Siew-Kwan Koh, Lei Zhou, Dylan Shaoying Goh, Hyungwon Choi, Hiromi Wai Ling Koh, Amanda Yun Rui Lam, Paik Shia Lim, Jodhbir S. Mehta, Jean-Paul Kovalik, Thomas M. Coffman, Hong Chang Tan, Yu-Chi Liu

Diabetes 2023;72(7):932–946

https://doi.org/10.2337/db22-0611

Published: 29 November 2022

View article titled, Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

Meeting Abstracts

41-OR: ADA President's Select Abstract: The Beneficial Effect of Fenofibrate on Diabetic Retinopathy Is Influenced by PPARA Genetic Variability and Is Mediated by an Increase in FGF21 Levels

MARIO LUCA MORIERI, HETAL SHAH, YALING TANG, CHRISTINE MENDONCA, JENNY MARIE JOBE, JOSYF MYCHALECKYJ, ALESSANDRO DORIA

Diabetes 2022;71(Supplement_1):41-OR

https://doi.org/10.2337/db22-41-OR

Published: 01 June 2022

View article titled, 41-OR: ADA President's Select Abstract: The Beneficial Effect of Fenofibrate on Diabetic Retinopathy Is Influenced by PPARA Genetic Variability and Is Mediated by an Increase in FGF21 Levels

Journal Articles

CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα

Mohamed A. Zayed, Xiaohua Jin, Chao Yang, Larisa Belaygorod, Connor Engel, Kshitij Desai, Nikolai Harroun, Omar Saffaf, Bruce W. Patterson, Fong-Fu Hsu, Clay F. Semenkovich

Diabetes 2021;70(2):549–561

https://doi.org/10.2337/db20-0635

Published: 19 December 2020

View article titled, CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα

Journal Articles

Pathogenic Role of PPARα Downregulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes

H. Greg Matlock, Fangfang Qiu, Volha Malechka, Kelu Zhou, Rui Cheng, Siribhinya Benyajati, Amy Whelchel, Dimitrios Karamichos, Jian-xing Ma

Diabetes 2020;69(6):1279–1291

https://doi.org/10.2337/db19-0898

Published: 25 March 2020

View article titled, Pathogenic Role of PPARα Downregulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes

Journal Articles

In This Issue of Diabetes

Diabetes 2020;69(4):497–498

https://doi.org/10.2337/db20-ti04

Published: 16 March 2020

View article titled, In This Issue of Diabetes

Journal Articles

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

Diabetes 2020;69(4):771–783

https://doi.org/10.2337/db19-0973

Published: 23 January 2020

View article titled, PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

Includes: Supplementary data

Journal Articles

A Protective Effect of PPARα in Endothelial Progenitor Cells Through Regulating Metabolism

Yan Shao, Jianglei Chen, Li-jie Dong, Xuemin He, Rui Cheng, Kelu Zhou, Juping Liu, Fangfang Qiu, Xiao-rong Li, Jian-xing Ma

Diabetes 2019;68(11):2131–2142

https://doi.org/10.2337/db18-1278

Published: 26 August 2019

View article titled, A Protective Effect of PPARα in Endothelial Progenitor Cells Through Regulating Metabolism

Includes: Supplementary data

Meeting Abstracts

139-LB: Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

ANDRZEJ S. JANUSZEWSKI, HAYDEN K. YOUNG, LIPING LI, RACHEL L. OCONNELL, TIMOTHY LYONS, CLARE B. KELLY, DAVID SULLIVAN, RUSSELL SCOTT, ANTHONY C. KEECH, ALICIA JENKINS

Diabetes 2019;68(Supplement_1):139-LB

https://doi.org/10.2337/db19-139-LB

Published: 01 June 2019

View article titled, 139-LB: Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

Meeting Abstracts

22-LB: Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD

JACOB YIMING CAO, BORIS WALDMAN, RACHEL L. OCONNELL, DAVID SULLIVAN, VAL GEBSKI, ANDRZEJ S. JANUSZEWSKI, IAN MARSCHNER, RUSSELL SCOTT, MARJA-RIITTA TASKINEN, R. JOHN SIMES, NEIL MCGILL, ALICIA J. JENKINS, ANTHONY C. KEECH

Diabetes 2019;68(Supplement_1):22-LB

https://doi.org/10.2337/db19-22-LB

Published: 01 June 2019

View article titled, 22-LB: Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD

Journal Articles

Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein

Jun Yuan, Joanne T.M. Tan, Kushwin Rajamani, Emma L. Solly, Emily J. King, Laura Lecce, Philippa J.L. Simpson, Yuen Ting Lam, Alicia J. Jenkins, Christina A. Bursill, Anthony C. Keech, Martin K.C. Ng

Diabetes 2019;68(5):1040–1053

https://doi.org/10.2337/db17-0926

Published: 14 February 2019

View article titled, Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein

Includes: Supplementary data

Journal Articles

An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes

Jonathan E. Noonan, Alicia J. Jenkins, Jian-Xing Ma, Anthony C. Keech, Jie Jin Wang, Ecosse L. Lamoureux

Diabetes 2013;62(12):3968–3975

https://doi.org/10.2337/db13-0800

Published: 16 November 2013

View article titled, An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes

Journal Articles

Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

Steven F. Abcouwer

Diabetes 2013;62(1):36–38

https://doi.org/10.2337/db12-1223

Published: 13 December 2012

View article titled, Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

Journal Articles

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

Ying Chen, Yang Hu, Mingkai Lin, Alicia J. Jenkins, Anthony C. Keech, Robert Mott, Timothy J. Lyons, Jian-xing Ma

Diabetes 2013;62(1):261–272

https://doi.org/10.2337/db11-0413

Published: 13 December 2012

View article titled, Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

Includes: Supplementary data

Journal Articles

Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Guenther Boden

Diabetes 2007;56(5):e4

https://doi.org/10.2337/db07-0216

Published: 01 May 2007

View article titled, Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Journal Articles

Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

J. Karalliedde, G.C. Viberti

Diabetes 2007;56(5):e3

https://doi.org/10.2337/db07-0146

Published: 01 May 2007

View article titled, Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Journal Articles

Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Guenther Boden

Diabetes 2007;56(5):e2

https://doi.org/10.2337/db07-0119

Published: 01 May 2007

Journal Articles

Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Jeffrey S. Stroup

Diabetes 2007;56(5):e1

https://doi.org/10.2337/db07-0082

Published: 01 May 2007

View article titled, Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

NARROW

Fenofibrate for Treating Diabetic Eye Disease

In This Issue of Diabetes

Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

41-OR: ADA President's Select Abstract: The Beneficial Effect of Fenofibrate on Diabetic Retinopathy Is Influenced by PPARA Genetic Variability and Is Mediated by an Increase in FGF21 Levels

CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα

Pathogenic Role of PPARα Downregulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes

In This Issue of Diabetes

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

A Protective Effect of PPARα in Endothelial Progenitor Cells Through Regulating Metabolism

139-LB: Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

22-LB: Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD

Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein

An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes

Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only